Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A2 | O43868 | 7/20 | 0.35 |
| ▸ | HSPA8 | P11142 | 3/20 | 0.35 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.33 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2587219 | 0.90 | HSPA8 (0.34) | SLC28A2HSPA8HSPA5RXFP1SLC29A1 | |
| SCHEMBL2584589 | 0.88 | HSPA8 (0.46) | SLC28A2HSPA8HSPA5RXFP1FBP1 | |
| SCHEMBL2584026 | 0.78 | ADK (0.36) | SLC28A2HSPA8HSPA5RXFP1 | |
| SCHEMBL2584222 | 0.78 | ADORA1 (0.37) | SLC28A2SLC29A1 | |
| SCHEMBL2583369 | 0.78 | SLC29A1 (0.33) | SLC28A2SLC29A1 | |
| SCHEMBL2579338 | 0.77 | HSPA8 (0.35) | SLC28A2HSPA8HSPA5RXFP1SLC29A1 | |
| SCHEMBL2584370 | 0.75 | HSPA8 (0.45) | SLC28A2HSPA8HSPA5RXFP1FBP1 | |
| SCHEMBL2584815 | 0.75 | HSPA5 (0.37) | SLC28A2HSPA8HSPA5RXFP1 | |
| SCHEMBL2583104 | 0.72 | CA1 (0.38) | — | |
| SCHEMBL2579342 | 0.70 | SMN1; SMN2 (0.38) | SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2018-10-16 | — | — | US | disclosed |
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | GILEAD SCIENCES, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2251015-B1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PHARMASSET, INC. | 2011-11-03 | — | — | US | disclosed |
| EP-2251015-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | Pharmasset, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | PHARMASSET, INC. | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | SLC29A1, PNP, SLC29A2 | SLC28A2 28/4885HSPA8 4823/4885HSPA5 1617/4885 |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PNP, ALPP, XDH | SLC28A2 177/4885HSPA8 4599/4885HSPA5 2063/4885 |
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, SLC29A2, PNP | SLC28A2 17/4885HSPA8 4839/4885HSPA5 2286/4885 |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, PNP, SLC29A2 | SLC28A2 29/4885HSPA8 4815/4885HSPA5 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.